» Articles » PMID: 38472981

Clinical Indicators of Bone Deterioration in Alcoholic Liver Cirrhosis and Chronic Alcohol Abuse: Looking Beyond Bone Fracture Occurrence

Abstract

Although previous studies indicated that chronic alcohol abuse (CAA) and alcoholic liver cirrhosis (ALC) are associated with increased bone fragility, understanding bone fragility determinants is still modest in these individuals. We used a comprehensive individualized clinical fracture risk assessment approach (vertebral osteodensitometry, femoral osteodensitometry and geometry, and serum bone turnover biomarkers) to compare adult male patients with ALC who have not previously had femoral or vertebral fractures ( = 39), patients with CAA (without liver cirrhosis, = 78) who have not previously had femoral or vertebral fractures and healthy age- and sex-matched controls ( = 43). Our data suggested that intertrochanteric bone mineral density was significantly lower in ALC and CAA patients than in controls. Also, the trabecular bone score was considerably lower in ALC patients compared with CAA and control individuals. The most significant inter-group differences in femoral geometry were noted on the femoral shaft. Patients with ALC and CAA have a higher 10-year risk of major osteoporotic fractures compared to the controls. Analysis of bone turnover biomarkers showed increased osteoprotegerin and beta-C-terminal telopeptide serum concentrations and decreased insulin growth factor-1 concentrations in patients with ALC compared to CAA and control groups. Our data revealed that bone alterations are present in patients with ALC and CAA even if they did not sustain a nontraumatic bone fracture, but it is also indicative that current bone-assessing clinical methods are not entirely reliable. Thus, future studies should focus on developing a reliable integrative clinical tool that can be used to accurately predict and prevent bone fracture occurrences in patients with ALC and CAA.

References
1.
Baim S, Miller P . Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009; 24(4):561-74. DOI: 10.1359/jbmr.090203. View

2.
Asrani S, Devarbhavi H, Eaton J, Kamath P . Burden of liver diseases in the world. J Hepatol. 2018; 70(1):151-171. DOI: 10.1016/j.jhep.2018.09.014. View

3.
Lupoli R, Di Minno A, Spadarella G, Ambrosino P, Panico A, Tarantino L . The risk of osteoporosis in patients with liver cirrhosis: a meta-analysis of literature studies. Clin Endocrinol (Oxf). 2015; 84(1):30-8. DOI: 10.1111/cen.12780. View

4.
Danford C, Trivedi H, Bonder A . Bone Health in Patients With Liver Diseases. J Clin Densitom. 2019; 23(2):212-222. DOI: 10.1016/j.jocd.2019.01.004. View

5.
Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santolaria-Fernandez F, Vega-Prieto M, Milena-Abril A, Sanchez-Perez M . Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. 2006; 41(3):261-6. DOI: 10.1093/alcalc/agl004. View